University of Alberta
Trial Pipeline
Screening for Prostate Cancer Using High Resolution Micro-ultrasound Versus Multiparametric Magnetic Resonance Imaging.
NCT06626022
Nimodipine Variability in SAH
NCT07065903
Trifecta-Lung cfDNA-MMDx Study
NCT05837663
Micro-UltraSound In Cancer - Active Surveillance
NCT05558241
Augmented Renal Clearance in Neurocritical Care
NCT07410624
Trifecta-Heart cfDNA-MMDx Study
NCT04707872
Effects of 5HTP on the Injured Human Spinal Cord
NCT04520178
Trifecta-Kidney cfDNA-MMDx Study
NCT04239703
Diagnostic and Therapeutic Applications of Microarrays in Liver Transplantation
NCT03193151
Novel MRI Biomarkers for Monitoring Disease Progression in ALS
NCT03362658
Diagnostic and Therapeutic Applications of Microarrays in Lung Transplantation
NCT02812290
Effectiveness of Robotic Gait Training and Physical Therapy for Children and Youth With Cerebral Palsy
NCT02391324
Diagnostic and Therapeutic Applications of Microarrays in Heart Transplantation
NCT02670408
Diagnostic and Therapeutic Applications in Microarrays in Organ Transplantation
NCT01299168
Electronic KIDCLOT Interactive Thrombosis/Thrombophilia Education; A Quality Assurance Initiative
NCT03910933
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 1 |
What the Pipeline for University of Alberta Shows
According to the ClinicalTrials.gov registry, University of Alberta is linked to 135 US clinical trials across every stage of research activity. Of those, 134 studies are currently recruiting — about 99% of the sponsor's indexed portfolio — and 0 are already marked complete, representing roughly 0% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for University of Alberta reports 1 late-stage studies (Phase 3 and Phase 4 combined) and 1 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for University of Alberta is Subarachnoid Hemorrhage, Aneurysmal with 2 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.